Table 3 Comparison of clinicopathological parameters in 78 patients with advanced hepatocellular carcinoma who received low-dose nivolumab
From: Low-dose nivolumab in advanced hepatocellular carcinoma
Characteristics | Nivolumab 100 mg (n = 61) | Nivolumab 20 mg (n = 17) | P value |
|---|---|---|---|
Age | 0.19 | ||
  < 60 years | 25 (41.0%) | 4 (23.5%) |  |
  ≥ 60 years | 36 (59.0%) | 13 (76.5%) |  |
Sex | 0.26 | ||
 Male | 15 (24.6%) | 2 (11.8%) |  |
 Female | 46 (75.4%) | 15 (88.2%) |  |
ECOG PS | 0.015* | ||
 0 | 31 (50.8%) | 3 (17.6%) |  |
 1 | 30 (49.2%) | 14 (82.4%) |  |
Child–Pugh classification | 0.30 | ||
 A | 47 (77.0%) | 11 (64.7%) |  |
 B (7) | 14 (23.0%) | 6 (35.3%) |  |
ALBI grade | 0.51 | ||
 1 | 27 (44.3%) | 6 (35.3%) |  |
 2 | 34 (55.7%) | 11 (64.7%) |  |
Hepatitis B | 0.13 | ||
 Yes | 41 (67.2%) | 8 (47.1%) |  |
 No | 20 (32.8%) | 9 (52.9%) |  |
Hepatitis C | 0.07 | ||
 Yes | 15 (24.6%) | 8 (47.1%) |  |
 No | 46 (75.4%) | 9 (52.9%) |  |
Macrovascular invasion (IVC, HV, PV) | 0.41 | ||
 Yes | 29 (47.5%) | 10 (58.8%) |  |
 No | 32 (52.5%) | 7 (41.2%) |  |
Main portal vein thrombosis | 0.75 | ||
 Yes | 9 (14.8%) | 2 (11.8%) |  |
 No | 52 (85.2%) | 15 (88.2%) |  |
History of hepatectomy | 0.89 | ||
 Yes | 24 (39.3%) | 7 (41.2%) |  |
 No | 37 (60.7%) | 10 (58.8%) |  |
Extrahepatic spread | 0.41 | ||
 Yes | 32 (52.5%) | 7 (41.2%) |  |
 No | 29 (47.5%) | 10 (58.8%) |  |
Lymph node metastasis | 0.95 | ||
 Yes | 21 (34.4%) | 6 (35.3%) |  |
 No | 40 (65.6%) | 11 (64.7%) |  |
Treatment lines | 0.32 | ||
 Second line | 37 (60.7%) | 8 (47.1%) |  |
 Third line and later lines | 24 (39.3%) | 9 (52.9%) |  |
AFP ≥ 400 ng/ml | 0.29 | ||
 Yes | 34 (55.7%) | 7 (41.2%) |  |
 No | 27 (44.3%) | 10 (58.8%) |  |